News

Evenity is an investigational bone-forming monoclonal antibody developed for the treatment of osteoporosis. The treatment is not yet approved by any regulatory authority. The decision has been taken

Ciclesonides are included in the corticosteroids class of medications, and are approved to treat asthma (Alvesco) and allergic rhinitis (Omnaris and Zetonna). “We are excited to announce this

It comes after an open research competition led by the National Institute for Health Research (NIHR). Following the success of this initial competition, a call for a second

The company, dubbed Qrativ, will leverage on the medical expertise and clinical data of Mayo Clinic’s and on the AI-driven knowledge synthesis platform of nference. Initially, Qrativ will focus

Under the deal, Sanofi will secure $97.5m upfront payment, as well as up to $27.5m based on the achievement of certain regulatory and manufacturing-related milestones. Once the deal

Biognosys' contract research services and tools are successfully applied in biomarker research, drug and target discovery, pathway modeling, mechanisms of action studies and many other areas. Its market

ALV-107 utilises the proprietary Alivio inflammation-targeting technology. The data were presented at the 2017 Drug Discovery and Therapy World Congress in Boston, Massachusetts. "One of the greatest needs

The Kyprolis-based regimen yielded positive results by meeting the key secondary endpoint of overall survival (OS) in what was a second phase 3 trial dubbed as ASPIRE conducted

The company has received approval for Tremfya to treat adults living with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is a